39.36 USD
▲-0.11+2.21%
盘后 38.51 0.00%
2026-08-03
市值
$8.12B
市盈率
—
EPS
-2.77
股息率
—
52 周区间
14.32 – 41.23
成交量
990.61K
Beta
0.77
目标价
46.88
52W 低 14.3252W 高 41.23
价格走势
公司简介
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Scienc...